Maverix Medical Closes Acquisition of Cirrus Bio as Foundation for Diagnostics Platform in Lung Cancer
Summary
MENLO PARK, Calif., March 29, 2024 /PRNewswire/ -- Maverix Medical, a dedicated lung cancer platform established by Ajax Health, KKR, and Hologic, Inc., today announced the acquisition of Cirrus Bio for an undisclosed amount. Cirrus Bio develops and brings to market multiomic solutions for the diagnosis and management of diseases where early detection plays a critical role in clinical outcomes. The first—Serpex Medical, announced at closing—has developed and obtained 510k clearance for steerable technologies that can precisely target lung tissue for biopsy or therapy delivery. We are far from the only ones working on this tough clinical problem, and we look forward to partnering with other innovators to discover and validate new techniques for improving lung cancer care," said David Mallery, CEO, Maverix Dx. With the support of its financial sponsors and advisors, KKR and Hologic, Maverix Medical continues to invest in both development- and commercial-stage lung cancer companies and welcomes opportunities to collaborate with innovators, entrepreneurs, clinicians, and industry leaders.